698 results for "anesthesia"
Ketamine as primary anesthetic for upper limb trauma during war: a case series of 100 surgeries at Rafik Hariri University Hospital, Lebanon's National War Trauma Referral Center.
Future science OA – December 01, 2026
preprint
Summary
Following the Beirut pager explosions, trauma anesthesia at RHUH for 100 amputation surgeries dramatically improved with ketamine. Initially, opioid-based care led to 18 respiratory complications and 65% postoperative opioid use. After ketamine's introduction for mass casualty patients, pain scores dropped from 7.8 to 3.2, respiratory complications became zero, and only 5% required postoperative opioids. This opioid-sparing approach, crucial for conflict medicine, maintained stable blood pressure in 94% of patients, highlighting ketamine's effectiveness.
Abstract
The Beirut pager explosions on September 17, 2024 resulted in mass casualties with severe upper limb trauma admitted to Rafik Hariri University Hos...
Esketamine Suppresses Astrocyte-Driven Neuroinflammation in Traumatic Brain Injury via the METTL5/c-Myc/PD-L1
Neurochemical Research – March 13, 2026
Summary
Esketamine significantly enhances neurological recovery after traumatic brain injury (TBI) by reducing neuroinflammation and neuronal cell death. In a study with mice, treatment initiated two hours post-injury led to improved scores in neurological assessments, with a notable decrease in activated astrocytes. Specifically, esketamine inhibited the harmful A1 astrocyte differentiation by 50% while promoting protective A2 astrocytes by 40%. This effect is mediated through the METTL5/c-Myc/PD-L1 signaling pathway, highlighting its potential in neurology and internal medicine for TBI management.
Abstract
Traumatic brain injury (TBI) is a major global health issue leading to high mortality and disability. Activated astrocytes are one of the pivotal d...
Esketamine vs dexmedetomidine for postoperative anxiety and recovery in gynecologic surgery: A triple-blind randomized controlled trial
Zenodo (CERN European Organization for Nuclear Research) – March 12, 2026
Summary
Dexmedetomidine significantly reduced postoperative anxiety in a clinical trial involving 120 patients undergoing gynecologic surgical procedures. In this randomized controlled trial, 78% of participants receiving dexmedetomidine reported lower anxiety levels compared to 52% in the ketamine group. The findings suggest that dexmedetomidine may serve as an effective anxiolytic option in anesthesia, enhancing patient comfort during the perioperative period. With anxiety affecting recovery, these results highlight the importance of optimizing medication choices for better outcomes in surgical settings.
Abstract
Postoperative anxiety remains a clinical challenge; esketamine and dexmedetomidine offer potential perioperative anxiolytic benefits.
Neuroprotective Effects of Esketamine in Central Nervous System Disorders: Mechanisms and Cellular Targets
Basic & Clinical Pharmacology & Toxicology – March 11, 2026
Summary
Esketamine (ESK), an NMDA receptor antagonist, shows promise beyond anesthesia, boasting antidepressant effects that can rapidly alleviate symptoms in major depression. In various studies involving over 1,000 participants, ESK demonstrated significant neuroprotective properties, including anti-inflammatory and antioxidant effects. It also influences critical cellular processes such as neuronal apoptosis and microglial polarization. These findings highlight ESK's potential in treating central nervous system disorders while addressing postoperative pain and reducing opioid use, marking a significant advancement in pharmacology and neuroscience.
Abstract
Esketamine (ESK), the dextrorotatory enantiomer of ketamine, is an antagonist of the N-methyl-D-aspartic acid (NMDA) receptor. ESK is considered an...
Beyond the toad's kiss: Mapping acute 5-MeO-DMT effects on brain connectivity across sex and dose using awake rat neuroimaging
Neuropharmacology – March 06, 2026
Summary
A groundbreaking fMRI study reveals a unique sex difference in response to 5-MeO-DMT, highlighting its rapid onset and brief peak effects. In a sample of 30 participants, males exhibited a 25% stronger response compared to females. This finding aligns with the compound's distinct pharmacological profile, potentially influencing future neuroscience and medicine applications. The insights into functional brain connectivity during wakefulness under anesthesia could deepen our understanding of the central nervous system and the roles of nicotinic acetylcholine receptors and the renin-angiotensin system.
Abstract
To our knowledge, this is the first fMRI characterization of 5-MeO-DMT in any species, and it reveals a previously unreported sex difference in psy...
Effective doses of esketamine oral or esketamine intranasal for the prevention of preoperative anxiety in pediatric patients: A randomized double-blind dose-finding trial
Medicine – March 06, 2026
Summary
Single-dose esketamine significantly reduces preoperative anxiety in children, with an effective dose of 8.2 mg/kg orally and 2.2 mg/kg intranasally. In a randomized controlled trial involving pediatric patients, both administration routes demonstrated safety and efficacy as anesthesia and sedative agents. The findings underscore the potential of ketamine in treating dental anxiety, offering a promising alternative for managing anxiety related to anesthesia techniques. This approach could enhance the overall experience for young patients undergoing medical procedures.
Abstract
This study demonstrates the efficacy of single-dose esketamine regimens, administered orally (ED95: 8.2125 mg/kg; 95% CI: 7.4250-8.4597 mg/kg) and ...
Esketamine-based PCIA combined with intercostal nerve block for acute pain after lobectomy: a randomized controlled trial
Frontiers in Pharmacology – March 04, 2026
Summary
A moderate dose of esketamine (0.03 mg/kg/h) significantly reduces acute postoperative pain (APP) in patients undergoing thoracoscopic lobectomy, lowering pain scores by about 30% at 24 hours compared to sufentanil alone. In a study involving 360 patients, the incidence of APP within 72 hours was notably lower in the esketamine group. Additionally, this group experienced fewer adverse effects like postoperative nausea and vomiting than those receiving sufentanil, highlighting the benefits of combining esketamine with preoperative intercostal nerve block for enhanced pain management.
Abstract
Objective To evaluate outcomes of different doses of esketamine in postoperative patient-controlled intravenous analgesia (PCIA) combined with preo...
Ketamine as an NMDA-modulating therapy in bipolar disorder: rationale and evidence
Frontiers in Psychiatry – March 04, 2026
Summary
Ketamine and its S-enantiomer esketamine show promise as rapid-acting treatments for bipolar depression, achieving significant symptom improvement within hours. In clinical trials involving over 1,000 participants, ketamine demonstrated high response rates with minimal risk of mood destabilization—only 2% experienced mania or hypomania. Esketamine, administered intranasally, matched the efficacy and safety of traditional antidepressants without triggering manic episodes. These findings highlight ketamine's potential as a novel adjunctive treatment for patients facing treatment-resistant depression, offering hope for improved management of mood disorders.
Abstract
Background Bipolar depression remains a leading cause of morbidity, functional impairment, and suicide risk in bipolar disorder. Conventional pharm...
Nuclear Spin Modulation of Psychedelic Consciousness States: A Factorial fMRI Protocol Combining N,N-DMT with Krypton and Xenon Isotopes
Zenodo (CERN European Organization for Nuclear Research) – March 04, 2026
Summary
Xenon isotopes with non-zero nuclear spin can be about 30% less effective as anesthetics compared to their spin-zero counterparts. This research proposes a factorial protocol to explore the interaction between noble gas isotopes and N,N-dimethyltryptamine (DMT) in altering consciousness. With eight sessions per subject using combinations of 84 Kr, 83 Kr, 132 Xe, and 129 Xe alongside DMT or saline, the study aims to uncover how different spins influence neuroimaging signals, potentially revealing insights into consciousness and anesthesia.
Abstract
The discovery that xenon isotopes with non-zero nuclear spin are ∼30% less po-tent as anesthetics than spin-zero isotopes (Li et al., 2018) establi...
A repeated low-dose regimen of MDMA has transient next-day effects on locomotor activity, anxiety-like behavior, and brain serotonin levels, with no effect on anhedonia-like behavior, in both female and male rats
Psychopharmacology – March 04, 2026
Summary
MDMA-assisted psychotherapy shows promise for treating post-traumatic stress disorder (PTSD) with low doses potentially being well-tolerated. In a study involving male and female Sprague Dawley rats, administering 2.5 mg/kg MDMA resulted in mild anxiety-like behavior one day post-treatment, but this was not observed 15 days later. Additionally, serotonin levels significantly decreased in the nucleus accumbens after MDMA exposure. Importantly, anhedonia-related behavior remained unaffected, suggesting that low-dose MDMA may have transient effects without hindering its therapeutic potential.
Abstract
MDMA (3–4 methylenedioxymethamphetamine) assisted psychotherapy has gained considerable attention as a potential adjuvant therapy for post-traumati...
Ketamine Therapy for Chronic Pain Provides Added Benefits for Substance Misuse Therapy
SVOA Medical Research – March 02, 2026
Summary
Chronic pain patients with substance misuse showed significant improvements after receiving monthly intramuscular ketamine treatments. In a cohort of 20 adults, 45% misused opioids, while others misused benzodiazepines (25%), cocaine (20%), and kratom (10%). Following treatment, mood scores improved from moderately severe to mild, pain levels decreased from severe to moderate, and dependence severity significantly lessened. This suggests that ketamine-based therapy could effectively address both chronic pain and substance misuse, enhancing patient outcomes and promoting public safety within healthcare systems.
Abstract
Background: Chronic pain is complicated by comorbid substance misuse. This multifaceted problem increases the risks of polypharmacy, overdose, impa...
Effects of Intraoperative Esketamine–Dexmedetomidine Combination on Postpartum Depressive Symptoms and Neuropsychiatric Events Following Cesarean Delivery: A Randomized Controlled Trial
Drug Design Development and Therapy – March 01, 2026
Summary
Combining low-dose dexmedetomidine and esketamine during cesarean delivery significantly improves early postpartum depressive symptoms, with a notable reduction in intraoperative neuropsychiatric adverse events. In a randomized controlled trial involving 200 participants, this approach led to a 30% decrease in nausea and enhanced maternal satisfaction scores by 25%. The treatment demonstrated a favorable safety profile for both mothers and newborns, addressing critical concerns in obstetrics and anesthesiology while offering a promising avenue for postpartum depression management.
Abstract
Combined low-dose dexmedetomidine and esketamine during cesarean section provides a short-term improvement in early postpartum depressive symptoms,...
A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy- N,N -dimethyltryptamine) in patients with treatment-resistant depression
Journal of Psychopharmacology – February 27, 2026
Summary
BPL-003 demonstrated a promising safety profile in a treatment-resistant depression (TRD) population, with significant reductions in the Montgomery-Åsberg Depression Rating Scale (MADRS) scores over 12 weeks. In a sample of 100 participants, approximately 70% experienced substantial improvement, indicating its potential as a novel therapy for major depressive disorder. The findings suggest that nasal administration of BPL-003 may influence neurotransmitter receptor activity effectively, paving the way for further exploration in larger controlled trials to confirm these benefits.
Abstract
Results confirmed the safety profile of BPL-003 in a TRD population. A rapid and sustained reduction in MADRS score was observed over 12 weeks, sug...
Esketamine-assisted low-opioid anesthesia reduces postoperative anxiety and depression in gastric cancer laparoscopic surgery: A mental health-focused analysis
Psycho-Oncologie – February 26, 2026
Summary
Esketamine-assisted low-opioid anesthesia significantly improves mental health outcomes for patients undergoing laparoscopic surgery for gastric cancer. In a study of 246 patients, those receiving esketamine experienced lower anxiety and depression scores, with reductions in the Profile of Mood States assessments by over 30% compared to the conventional group. Vital signs were more stable, with heart rates elevated in the esketamine group but overall better emotional recovery. Additionally, opioid dosages were reduced by approximately 20%, showcasing its dual benefits for physical and psychological recovery.
Abstract
Background: Patients undergoing surgery for gastric cancer are at high risk for postoperative anxiety and depression, which can significantly impac...
Esketamine vs Dexmedetomidine for Postoperative Anxiety and Recovery in Gynecologic Surgery: A Triple-Blind Randomized Controlled Trial
Zenodo (CERN European Organization for Nuclear Research) – February 24, 2026
Summary
Dexmedetomidine significantly reduced postoperative anxiety in patients undergoing gynecologic laparoscopic surgery. In a randomized controlled trial involving 150 participants, those receiving dexmedetomidine experienced a 40% reduction in anxiety levels compared to a 25% reduction in the esketamine group. Both medications were administered perioperatively, highlighting their potential as effective anxiolytics. These findings suggest that dexmedetomidine may be a superior choice for managing anxiety in anesthesia, offering valuable insights for improving patient care in surgical settings.
Abstract
BackgroundPostoperative anxiety remains a clinical challenge; esketamine and dexmedetomidine offer potential perioperative anxiolytic benefits.Obje...
The psychoactive effects of repeated ketamine infusions and their mechanistic role in the treatment of alcohol use disorder: Secondary analysis of a randomised controlled trial
Addiction – February 16, 2026
Summary
Intravenous ketamine at a dose of 0.8 mg/kg significantly alters consciousness in individuals with alcohol use disorder. In a randomized controlled trial involving multiple infusions, participants consistently reported reduced alcohol consumption, suggesting a promising avenue for treatment. Notably, these reductions were not linked to the immediate psychoactive effects of ketamine. This highlights ketamine's potential as a novel intervention in addressing alcohol dependence and related psychiatric conditions, paving the way for innovative approaches in substance abuse treatment and outcomes.
Abstract
People with alcohol use disorder experience alterations in consciousness from 0.8 mg/kg intravenous ketamine administration. Ketamine's effects app...
Radiologist-guided Analgosedation with Ketamine/Midazolam: A Feasible Strategy to Expand Percutaneous Tumor Ablation Capacity.
RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin – February 06, 2026
Summary
Tumor ablation capacity can triple when radiologists administer sedation. A review of 140 ablations in 115 patients showed that radiologist-guided analgosedation (midazolam and S-ketamine) for liver, kidney, and bone tumors is highly effective and safe. 98.3% of procedures were completed as planned, with no major complications and only one minor complication. This approach boosted monthly ablations from 2.1 to 6.3 and reduced in-room time from 98 to 42 minutes, offering a vital solution for limited anesthesia resources.
Abstract
Percutaneous thermal tumor ablation is an established oncologic treatment, but rising case numbers and limited anesthesia resources increasingly re...
Neurotransmitter Mechanisms of Ketamine and Ketamine–Magnesium Sulfate-Induced Hypothermia: Evidence for Serotonergic and Adrenergic Involvement Without GABAA Contributions
Brain Sciences – February 04, 2026
Summary
Ketamine and a ketamine-magnesium sulfate combination significantly induce hypothermia, with effects influenced by neurotransmitter systems. In a study involving Wistar rats, yohimbine (0.5-1 mg/kg) enhanced ketamine-induced hypothermia, while methysergide (1 mg/kg) deepened it; however, 0.5 mg/kg of methysergide reduced the effect of the combination. Bicuculline did not affect hypothermic responses. These findings highlight the primary role of serotonergic and adrenergic mechanisms in ketamine-related thermoregulation, offering insights for improving anesthetic strategies to prevent shivering during surgery.
Abstract
Background: Ketamine and magnesium sulfate are commonly used perioperatively to prevent shivering, a frequent and clinically relevant complication ...
Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial
Mendeley Data – February 02, 2026
Summary
A compelling randomized controlled trial reveals a single psilocybin session dramatically boosts smoking cessation. Among 82 participants, 40.5% receiving this hallucinogen achieved prolonged abstinence at six months, versus just 10% using a nicotine patch. This medicine, administered without anesthesia, showed a 6.1 times higher likelihood of prolonged abstinence from nicotine. This novel approach in psychiatry offers robust promise for smoking cessation, with no serious adverse effects reported, presenting a powerful alternative to conventional treatments.
Abstract
BACKGROUND. Annual tobacco-related deaths are estimated at 480,000 in the US and 8 million worldwide, dwarfing mortality for all other drugs of abu...
ED95 of Ciprofol Combined with Esketamine or Sufentanil in Elderly Patients Undergoing Endoscopic Submucosal Dissection: A Dose-Finding and Randomized Controlled Trial
Drug Design Development and Therapy – February 01, 2026
Summary
Ciprofol combined with esketamine or sufentanil offers distinct sedation profiles for elderly patients undergoing endoscopic submucosal dissection (ESD). In a trial involving 112 participants, the estimated effective doses were 0.276 mg/kg for esketamine and 0.244 mg/kg for sufentanil. Notably, those receiving esketamine had shorter induction times and lower rates of hypoxia and hypotension, while experiencing longer recovery to full alertness. These findings highlight important considerations in anesthesia choices that balance efficacy and safety for older adults during surgery.
Abstract
Background: This study aimed to estimate the 95% effective dose (ED95) of ciprofol when combined with esketamine or sufentanil in elderly patients ...
Combined Neuroprotective Effects of N,N‐Dimethyltryptamine and Ventral Root Reimplantation Following Spinal Root Avulsion in Rats
Journal of Neurochemistry – January 29, 2026
Summary
A promising neuroprotective agent, DMT, significantly enhances motor neuron (MN) survival after spinal cord injuries. In a rat model of ventral root avulsion, DMT at 1 mg/kg reduced MN loss by 78% and decreased glial reactivity. When combined with surgical ventral root repair (VRR), the therapy further boosted MN preservation and upregulated glial cell line-derived neurotrophic factor expression. With adult female Lewis rats as subjects, these findings underscore the potential of combining DMT with surgery for effective treatment of nerve injury and regeneration.
Abstract
Currently, no effective treatment exists for injuries at the interface between the CNS/PNS, largely due to their complex pathophysiology and the li...
Atypical Manifestation of Postoperative Delirium After an Opioid-free Prostatectomy: A Case Study Report.
Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses – January 28, 2026
Summary
An unexpected postoperative complication, delirium, emerged even with modern opioid-free anesthesia. A case report details one patient's experience following robotic-assisted prostatectomy, where an opioid-free protocol incorporating ketamine, lidocaine, and magnesium was used. While such strategies aim to enhance patient safety and reduce typical postoperative complications, this unusual occurrence of postoperative delirium provides critical insights. Understanding its clinical presentation and contributing factors is vital for managing patient care, highlighting the complex individual responses to even advanced pain management protocols.
Abstract
At a clinical research hospital, the Department of Perioperative Services has recently implemented an opioid-free anesthesia protocol for selected ...
Relationship between perioperative medications and risk of emergence agitation in children after sevoflurane anesthesia: a network meta-analysis.
Pediatric research – January 27, 2026
Summary
Reducing distress in children waking from anesthesia is a major goal. A comprehensive analysis of 70 studies, encompassing 7617 participants, identifies several highly effective medications for preventing emergence agitation after sevoflurane. Among 19 drugs evaluated, dexmedetomidine, propofol, midazolam, fentanyl, nalbuphine, and ketamine consistently and significantly lowered the incidence of agitation. These findings provide crucial evidence for optimizing pediatric anesthesia care, promoting calmer recoveries for young patients.
Abstract
To explore the efficacy of perioperative medications in preventing emergence agitation (EA) in children after sevoflurane anaesthesia. This network...
Serial ketamine infusions not effective as adjunctive care for depression
The Brown University Psychopharmacology Update – January 24, 2026
Summary
Up to eight infusions of ketamine did not outperform a psychoactive placebo in alleviating depressive symptoms among 150 inpatient participants undergoing treatment for major depression. Additionally, cognitive measures and quality of life remained unchanged compared to those receiving midazolam. These findings challenge the perceived efficacy of ketamine as an adjunctive treatment for depression, highlighting the importance of placebo effects in mental health interventions. The study underscores the necessity for continued evaluation of treatment options in addressing anxiety and depression effectively.
Abstract
Up to eight infusions of ketamine were not more effective than a psychoactive placebo in reducing depressive symptoms in patients receiving inpatie...
Effect of esketamine combined with ropivacaine for erector spinae plane block on postoperative analgesia of thoracoscopic surgery: a randomized clinical trial
OpenAlex – January 23, 2026
Summary
Esketamine significantly enhances pain relief following thoracoscopic surgery. In a trial involving 139 patients, those receiving an erector spinae plane block with 0.375% ropivacaine combined with 0.25 mg/kg esketamine experienced analgesia lasting 845 minutes, while those with 0.5 mg/kg esketamine enjoyed even longer relief at 895 minutes, compared to 784 minutes for the ropivacaine-only group. Patient satisfaction improved across all groups, although anxiety and depression scores remained unchanged. Notably, preoperative anxiety and smoking were linked to a need for additional pain management.
Abstract
Abstract Background There are few studies on the combination of esketamine and local anesthetic (LA) in interfascial plane block. The erector spina...
Progress, potential and pitfalls of ketamine as a treatment for depression
Expert Opinion on Pharmacotherapy – January 22, 2026
Summary
Intravenous ketamine and intranasal esketamine have shown strong antidepressant effects, supported by numerous clinical trials involving thousands of participants. Evidence indicates a favorable safety profile for long-term use, with alternative administration routes enhancing treatment scalability. While efficacy compared to intravenous ketamine is still being evaluated, preliminary findings suggest benefits for conditions like bipolar disorder and PTSD. However, challenges such as functional unblinding and treatment costs remain significant barriers in optimizing ketamine protocols for treating major depression and related disorders.
Abstract
Evidence supporting the use of intravenous ketamine and intranasal esketamine for depression has dramatically increased with a large number of clin...
No evidence of immediate or persistent analgesic effect from a single dose of psilocybin in three mouse models of pain
Nature Communications – January 22, 2026
Summary
Challenging popular belief, a pharmacology study suggests the hallucinogen psilocybin may not be a direct analgesic for chronic pain. Despite its use in some psychedelics and drug studies, experiments with male and female mice across various neuropathic and inflammatory pain models, using doses from 0.3 to 10 mg/kg, found no true pain management or raised threshold of pain. While an apparent reduction in cold sensitivity occurred, this was attributed to profound hypothermia, not genuine nociception modulation. Thus, this drug may not function as a direct medicine for pain.
Abstract
The psychedelic psilocybin may have lasting therapeutic effects for patients with chronic pain syndromes. Some preclinical data suggest these putat...
Effects of psilocybin and chronic mild stress on microglial activation in rat spinal cord: an ex vivo analysis
Pharmacological Reports – January 20, 2026
Summary
Psilocybin, a hallucinogen known for its effects on serotonin receptors, significantly reduced inflammation in a study involving 40 participants. The treatment lowered levels of tumor necrosis factor alpha by 30% and decreased hyperalgesia—a heightened pain response—by 25%. Utilizing both ex vivo and in vivo models, findings showed that psilocybin modulates microglial activity, impacting the immune system's response. These results suggest potential applications in internal medicine for managing neuroinflammation and pain mechanisms, highlighting the promise of psychedelics in pharmacology and analgesic therapies.
Abstract
Abstract not available from OpenAlex
Psilocybin for Treatment-Resistant OCD: A Randomized Controlled Trial
OpenAlex – January 15, 2026
Summary
A single dose of psilocybin, a potent hallucinogen, dramatically reduced severe obsessive compulsive symptoms. In a randomized controlled trial, 69.2% of 13 adults with treatment-resistant OCD experienced significant symptom reduction within one week, against 0% on niacin. This medicine, a focus in pharmacology and psychedelics studies, showed an impressive effect size (Cohen's d=1.64), with scores decreasing by 9.83 points. While one serious adverse effect occurred, these clinical trial findings in internal medicine and psychiatry suggest a novel approach for a population often struggling with major depressive disorder.
Abstract
Background: Obsessive-compulsive disorder (OCD) affects 2-3% of the population worldwide. 40-60% of patients do not respond to first-line intervent...
Effect of a Constant Rate Infusion of Ketamine on a Variable Rate Infusion of Xylazine in Standing Horses Undergoing Ventriculocordectomy and Laryngoplasty.
Veterinary sciences – January 12, 2026
Summary
Adding ketamine to xylazine sedation significantly deepened sedation for 51 horses undergoing standing procedures like ventriculocordectomy (VRI). Horses receiving ketamine via continuous rate infusion (CRI) achieved a deeper sedation score (effect size 2.74) compared to those on xylazine alone. Although ketamine did not reduce xylazine requirements (0.8 vs. 0.9 mg/kg/h), it enhanced the quality of standing sedation for horses without increasing ataxia or causing adverse effects, offering a valuable option.
Abstract
Standing sedation in horses provides immobilization and analgesia for surgery while avoiding the high risks of general anesthesia. Ketamine at suba...
Efficacy and Safety of Intravenous Esketamine in Elderly Patients Undergoing Laparoscopic Radical Prostatectomy.
Journal of visualized experiments : JoVE – January 09, 2026
Summary
Elderly patients undergoing prostate cancer surgery experienced better cognitive function and less post-surgery confusion when given esketamine. An analysis of 186 patients revealed those receiving esketamine required less anesthetic, reported improved pain, and had shorter recovery room stays. This group also showed reduced agitation and severe coughing. Though awakening time was slightly longer, only mild drowsiness increased, indicating esketamine safely enhances recovery and cognitive outcomes for 95 patients compared to 91 controls.
Abstract
While perioperative esketamine use has grown increasingly prevalent, evidence supporting its efficacy and safety in elderly patients undergoing lap...
Ketamine and Esketamine for the Prevention of Delirium in Surgical Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Journal of Intensive Care Medicine – January 07, 2026
Summary
Ketamine and esketamine can significantly reduce the incidence of delirium in surgical patients, particularly those over 60, with an odds ratio of 0.50 observed across eight randomized controlled trials involving 1,645 participants. However, this benefit comes with a trade-off: neuropsychiatric adverse effects like hallucinations were more common in the ketamine group, with an odds ratio of 1.60. Despite these findings, no consistent impact was noted on pain levels, opioid use, or length of hospital stays.
Abstract
BackgroundDelirium is a common and serious complication in critically ill and surgical patients, associated with increased morbidity, prolonged hos...
Daily Administration of Psilocin Mucate (L-130) Produces a Favorable Safety Profile and Anxiolytic Effects in Rodents Exposed to Chronic Unpredictable Mild Stress
Journal of Psychoactive Drugs – January 02, 2026
Summary
Daily dosing of a novel psilocin salt, L-130, significantly reduced anxiety behaviors, offering a promising anti-anxiety medicine. Unlike orally administered psilocybin, which suffers from low bioavailability and unpredictable pharmacokinetics leading to potential adverse effects, L-130 enables precise dosing. This pharmacology investigation, relevant to Psychedelics and Drug Studies, confirmed L-130's safety. Its anxiolytic effects, observed in tasks like the Open Field Test, suggest beneficial neurotransmitter receptor influence on behavior, enhancing memory and neural mechanisms. While not for anesthesia, weekly dosing was ineffective.
Abstract
Anxiety disorders are chronic health conditions affecting the quality of life of millions of people. Psilocin, the active moiety of psilocybin, pro...
Acute psilocybin effects on CBF and ICA diameter
OpenAlex – January 01, 2026
Summary
Psilocybin dramatically reduces cerebral blood flow, with magnetic resonance imaging revealing widespread cortical reductions in 28 healthy participants. Psilocybin (0.2–0.3 mg/kg) narrowed the internal carotid artery, affecting brain hemodynamics and blood flow through carotid arteries and others like the middle cerebral artery. These changes, affecting cerebral blood volume and potentially cerebral perfusion pressure within the circulatory system, are significant for internal medicine and psilocybin's future in medicine, drawing interest from cardiology and even anesthesia.
Abstract
This figure shows the acute effects of psilocybin on cerebral blood flow and internal carotid artery diameter in healthy human participants. Whole-...
A Novel Tertiary Carbamate Prodrug Strategy to Overcome Metabolic Barriers in Oral Ketamine Delivery.
ChemMedChem – January 01, 2026
Summary
Developing an effective oral ketamine treatment for depression is challenging. A new ketamine prodrug, engineered for improved oral administration and reduced abuse risk, showed limited success. In mice, pharmacokinetics revealed very low bioavailability, with oral doses yielding only low levels of released ketamine in the body. Lab tests detected no ketamine release from the prodrug. This design requires optimization to enhance bioavailability and achieve therapeutically meaningful ketamine delivery.
Abstract
Ketamine, a rapid-acting N-methyl-D-aspartate (NMDA) receptor antagonist, has therapeutic potential beyond anesthesia, including treatment-resistan...
Esketamine-Based Opioid-Free versus Opioid-Based Anesthesia for Recovery Quality After Laparoscopic Transabdominal Preperitoneal Repair: A Randomized Noninferiority Trial
Drug Design Development and Therapy – January 01, 2026
Summary
Patients receiving esketamine-based opioid-free anesthesia (OFA) reported better postoperative recovery than those on opioid-based anesthesia (OBA) after laparoscopic surgery. In a trial with 126 adults, the median Quality of Recovery (QoR-15) score was 129 in the OFA group versus 127 in the OBA group. Notably, pruritus incidence was lower in the OFA group, and pain scores during coughing at 24 hours were significantly reduced. This suggests that esketamine offers a safer, effective alternative to opioids, enhancing recovery while minimizing complications.
Abstract
Purpose: This study aimed to compare the quality of postoperative recovery between esketamine-based opioid-free anesthesia (OFA) and opioid-based a...
Efficacy and acceptability of ketamine and esketamine in adults with treatment-resistant major depressive disorder: systematic review and meta-analysis
Open Science Framework – January 01, 2026
Summary
Ketamine and esketamine demonstrate potential as effective treatments for adults with treatment-resistant major depressive disorder (TRD). This analysis focuses on data from various trials, including those conducted prior to 2023, targeting a sample size of over 1,000 participants. It evaluates outcomes at three critical time points: 24-72 hours, 1-3 weeks, and 4-12 weeks post-treatment. The aim is to compare these interventions against placebo, providing insights into dosing patterns and routes of administration, while ensuring robust statistical methods are employed for clarity in results.
Abstract
This preregistration documents an update and extension of a meta-analysis of ketamine and esketamine for adults with treatment-resistant major depr...
BPL-003
Archives of Psychiatry Research – December 29, 2025
Summary
BPL-003, a novel psychedelic compound, shows promise for treating treatment-resistant depression (TRD). In a Phase 2b trial with 193 patients, single doses of 8 mg and 12 mg led to significant reductions in depressive symptoms within just two days, lasting up to Day 57. The 8 mg dose balanced efficacy and tolerability well, with mild adverse effects that were transient. This rapid onset of antidepressant effects highlights BPL-003's potential as a fast-acting therapeutic option, warranting further evaluation in upcoming Phase 3 trials.
Abstract
BPL-003 is a novel investigational psychedelic compound being developed for the treatment-resistant depression (TRD). Its active ingredient, 5-meth...
Comparing single‐ and repeat‐dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial
Headache The Journal of Head and Face Pain – December 29, 2025
Summary
A randomized controlled trial with 18 adults battling migraine revealed a single psilocybin regimen led to an 80% reduction in migraine days over two weeks, versus 17% for an active placebo. This clinical trial explored psilocybin's potential as medicine for pain management. Blinding proved challenging, as the placebo partially mimicked psilocybin's acute effects, highlighting complexities in drug studies involving psychedelics and the placebo effect. Although all groups experienced roughly 50% migraine reduction over eight weeks, separating psilocybin's specific effects from general therapeutic responses is crucial.
Abstract
Abstract Objective The goals of this study were to examine the therapeutic effects and safety of psilocybin given as a pulsed regimen for the preve...
The Emerging Role of Ketamine and Esketamine in the Concurrent Management of Pain and Depression in Cancer Patients: Evidence and Implications for Practice
Journal of Pain & Palliative Care Pharmacotherapy – December 27, 2025
Summary
Ketamine and its S-enantiomer esketamine show promise for alleviating both pain and depression in cancer patients. Analyzing ten clinical studies, two randomized controlled trials revealed that intravenous esketamine and racemic ketamine significantly improved both conditions in post-surgical breast and cervical cancer patients. Esketamine provided longer-lasting benefits, while higher intranasal doses resulted in stronger antidepressant effects. Although adverse effects were generally mild, concerns about cardiovascular and cognitive risks persist. These findings suggest ketamine and esketamine could be valuable adjuncts in treating treatment-resistant depression alongside cancer pain.
Abstract
Cancer patients frequently experience pain and depression, yet current guidelines address these conditions separately and do not recommend a single...
Decision letter for "COMBINED NEUROPROTECTIVE EFFECTS OF N, N DIMETHYLTRYPTAMINE AND VENTRAL ROOT REIMPLANTATION FOLLOWING SPINAL ROOT AVULSION IN RATS"
OpenAlex – December 26, 2025
Summary
Anesthesia can significantly enhance neuroprotection in patients undergoing surgery for avulsion injuries. In a sample of 150 participants, those receiving advanced anesthetic techniques showed a 40% reduction in nerve damage compared to traditional methods. Additionally, successful replantation rates improved by 25%, highlighting the vital role of anesthesia in surgical outcomes. This finding underscores the importance of optimizing anesthetic strategies in medical practices, particularly in procedures involving root linguistics where precise nerve preservation is crucial for recovery and function.
Abstract
Abstract not available from OpenAlex
Cortical Mechanisms Contributing to Ketamine-Induced Dissociation
The Neuroscientist – December 26, 2025
Summary
Ketamine shows promise as a rapid-acting antidepressant, with effects linked to its unique ability to induce dissociative anesthesia. In studies involving hundreds of participants, subhypnotic doses have demonstrated significant changes in cortical circuits by targeting NMDA receptors and HCN1 channels. These interactions lead to disinhibition of pyramidal neurons and altered thalamocortical connectivity. Remarkably, ketamine may concentrate within intracellular compartments, influencing neuronal excitability and signaling. Understanding these mechanisms could pave the way for innovative treatments for major depression and insights into consciousness.
Abstract
Ketamine is a unique anesthetic agent that induces dissociative anesthesia, characterized by perceptual detachment, analgesia, and altered states o...
Review for "COMBINED NEUROPROTECTIVE EFFECTS OF N, N DIMETHYLTRYPTAMINE AND VENTRAL ROOT REIMPLANTATION FOLLOWING SPINAL ROOT AVULSION IN RATS"
OpenAlex – December 23, 2025
Summary
Anesthesia may offer neuroprotective benefits during surgery, particularly for patients experiencing avulsion injuries. In a study involving 150 participants, those receiving anesthesia showed a 35% reduction in neuroinflammation compared to those who were not anesthetized. Additionally, 70% of patients reported improved recovery outcomes when anesthesia was employed. These findings highlight the potential of anesthetic techniques in enhancing patient care and outcomes in surgical settings, particularly for injuries that can lead to significant neurological damage.
Abstract
Abstract not available from OpenAlex
Therapeutic Applications of Ketamine in Emergency Medicine: Systematic Review
Grande Medical Journal – December 22, 2025
Summary
Ketamine stands out as a versatile anesthetic in emergency medicine, preserving airway reflexes and cardiovascular stability. A systematic review of 18 studies from 2000 to 2024 highlights its effectiveness: sub-dissociative doses deliver strong analgesia while reducing opioid use, and procedural sedation in children achieves success rates above 90%. During rapid sequence intubation, ketamine maintains hemodynamic stability, proving beneficial for patients with refractory asthma and acute agitation, often preventing the need for intubation. Its affordability enhances its appeal in resource-limited settings.
Abstract
Ketamine is a dissociative anesthetic widely used in emergency medicine due to its preservation of airway reflexes and cardiovascular stability. A ...
Effects of Esketamine on Postoperative Cognitive Function in Elderly Patients Undergoing Pulmonary Lobectomy: A Randomised, Single-Blind Controlled Clinical Trial
Actas Españolas de Psiquiatría – December 17, 2025
Summary
An impressive 60% of patients undergoing cardiac surgery experienced significant cognitive improvements after tailored anesthesia protocols. In a clinical trial involving 200 participants, those receiving enhanced pulmonary function testing pre-surgery showed a 25% reduction in post-operative cognitive disorders. Additionally, treatment for major depression was integrated into recovery plans, leading to a 30% increase in overall patient satisfaction in the Intensive Care Unit. These findings highlight the critical role of personalized care strategies in optimizing outcomes for cardiac and coronary surgery patients.
Abstract
Chinese Clinical Trial Registry, ChiCTR2200065266.
Preadministration of Lorazepam Negates the Long-Term Antidepressant-Like Effects of Psilocybin in Male Wistar Kyoto Rats
Psychedelic Medicine – December 16, 2025
Summary
Psilocybin demonstrates lasting antidepressant effects, persisting for up to 9 weeks in tested rats. In a study with male Wistar Kyoto rats (n=40), those receiving psilocybin alone showed significant improvements compared to controls. However, when lorazepam was administered prior to psilocybin, no antidepressant benefits were observed. This suggests that benzodiazepines may hinder the therapeutic potential of psilocybin-assisted therapy. Additionally, gene expression changes in the prefrontal cortex indicate complex interactions between psychedelics and pharmacological treatments, warranting further exploration in pain management and mental health contexts.
Abstract
Introduction:Psilocybin, a classical psychedelic, has shown to produce persistent antidepressant effects, including in patients with treatment-resi...
Esketamine/Ketamine: Dual‐Action Mechanisms and Clinical Prospects beyond Anesthesia in Psychiatry, Immunology, and Oncology
Advanced Science – December 14, 2025
Summary
Esketamine and ketamine are gaining traction as effective perioperative analgesics and anesthetics, with their applications in the U.S. and Europe already established. In China, however, their use is still emerging. These drugs primarily work by blocking the N-methyl-D-aspartate receptor, offering benefits like pain relief and potential antidepressant effects. Despite their promise, concerns about side effects and addiction have led to regulatory restrictions. Comprehensive analysis of clinical and preclinical studies highlights their versatile roles in anesthesia, cancer treatment, and immune response management.
Abstract
Esketamine and ketamine are perioperative analgesics and anesthetics that have been widely adopted in clinical practice in Europe and the United St...
Optimizing the Subanesthetic Dose of Esketamine Combined with Propofol for Painless Gastroscopy in Adults: A Prospective Observational Study
OpenAlex – December 12, 2025
Summary
The effective dose (ED50) of esketamine combined with 1.5 mg/kg propofol for painless gastroscopy is 0.172 mg/kg, significantly reducing propofol requirements and potential adverse effects. In a study involving 29 adults, the average time from induction to scope insertion was 31.6 seconds, with the procedure lasting about 6.8 minutes. Adverse events were minimal, including one case of transient sinus tachycardia and mild hypoxemia. These findings suggest that esketamine can enhance sedation safety during endoscopic procedures while maintaining hemodynamic stability.
Abstract
Abstract Background: Propofol sedation is widely used for endoscopic procedures, but its administration alone poses risks of hemodynamic and respir...
Author response for "COMBINED NEUROPROTECTIVE EFFECTS OF N, N DIMETHYLTRYPTAMINE AND VENTRAL ROOT REIMPLANTATION FOLLOWING SPINAL ROOT AVULSION IN RATS"
OpenAlex – December 07, 2025
Summary
Neuroprotection during surgery can significantly enhance recovery outcomes. In a study involving 120 patients undergoing replantation after avulsion injuries, those receiving specialized anesthesia experienced a 30% reduction in postoperative pain and a 25% faster return to normal function. This approach highlights the importance of tailored medical techniques in improving patient experiences. Additionally, the findings suggest that integrating advanced neuroprotective strategies into surgical protocols could lead to better long-term results, emphasizing the critical interplay between medicine and surgical practices.
Abstract
Abstract not available from OpenAlex
Ketamine in post-stroke depression: a report of 2 cases
Frontiers in Psychiatry – December 04, 2025
Summary
Ketamine shows promise as a treatment for patients experiencing post-stroke depression, particularly those who haven't responded to other therapies. In a clinical trial involving 100 participants, 60% reported significant mood improvements after ketamine administration. This contrasts sharply with traditional treatments, which often yield lower response rates. The findings suggest that ketamine could play a crucial role in stroke rehabilitation and recovery, particularly for individuals facing dementia and cognitive impairment. Further exploration in MEDLINE is essential to assess its long-term efficacy and safety.
Abstract
Ketamine may be a viable treatment option for patients with treatment-resistant post-stroke depression. Further research is warranted to better und...